Chordia Therapeutics (TSE:190A) Forward Dividend Yield %: 0.00% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Forward Dividend Yield %?

Chordia Therapeutics TSE:190A -2.53% 11 Forward Dividend Yield % is 0.00% as of Jul. 21, 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 149 Biotechnology companies, Chordia Therapeutics ranks worse than 671140.27% on this metric.

As of today (2026-07-21), the Forward Annual Dividend Yield of Chordia Therapeutics is 0.00%.

As of today (2026-07-21), the Trailing Annual Dividend Yield of Chordia Therapeutics is 0.00%.

TSE:190A's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Forward Dividend Yield % only.

Chordia Therapeutics's Dividends per Share for the six months ended in Feb. 2026 was 円0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Chordia Therapeutics  (TSE:190A) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Chordia Therapeutics Forward Dividend Yield % Related Terms

TSE:190A vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Chordia Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordia Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's Forward Dividend Yield % falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Chordia Therapeutics (TSE:190A) has a Forward Dividend Yield % of 0.00% as of Jul. 21, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry.
Is Chordia Therapeutics' Forward Dividend Yield % too high?
Chordia Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Chordia Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Chordia Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.36, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Chordia Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordia Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Forward Dividend Yield % is 0.00% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price